Lauer Wealth’s CRISPR Therapeutics CRSP Stock Holding History

Lauer Wealth’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-10,600	Closed	-$38.2K	–	39
2024 Q3	$38.2K	Buy	+10,600	New	+$538K	0.03%	37

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Lauer Wealth's CRSP Position: Q2 2023 in Review

Lauer Wealth sold out of CRISPR Therapeutics (CRSP) in Q2 2023, closing a stake of 4,030 shares — an estimated $210K sold.

Lauer Wealth first reported a position in CRSP in Q1 2023 and held it in 1 quarter. The position peaked at $210K in Q1 2023. 418 funds tracked by Wall St. Rank hold CRSP as of Q2 2023.

Lauer Wealth reported no remaining CRISPR Therapeutics position as of Q2 2023 after selling out during the quarter.
Lauer Wealth sold 4,030 CRISPR Therapeutics shares in Q2 2023, an estimated $210K.
Lauer Wealth first reported a position in CRISPR Therapeutics in Q1 2023 and held it in 1 quarter.
Lauer Wealth's CRISPR Therapeutics position peaked at $210K in Q1 2023.
418 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2023.

Based on Lauer Wealth's 13F filing for Q2 2023, filed 3 Aug 2023.